Key regions: South Korea, Japan, Europe, Brazil, United Kingdom
The Other Pharmaceuticals market in Nigeria has been experiencing significant growth in recent years.
Customer preferences: The Nigerian population has been showing an increasing demand for healthcare products, including pharmaceuticals. The rise in demand can be attributed to the growing awareness of health issues and the need for preventive measures. Additionally, the expanding middle class and the increasing number of people with disposable income have contributed to the growth of the Other Pharmaceuticals market.
Trends in the market: The Other Pharmaceuticals market in Nigeria has been characterized by the increasing number of local manufacturers and the growing number of imported products. The market has been experiencing a shift towards the production of generic drugs, which are cheaper alternatives to branded drugs. The trend towards generic drugs can be attributed to the increasing awareness of the population about the availability of cheaper alternatives and the need to reduce healthcare costs.
Local special circumstances: The Nigerian pharmaceutical market is highly regulated, and the government has been implementing policies to promote local production and reduce the dependence on imported products. The government has been providing incentives to local manufacturers to encourage local production and has been implementing policies to reduce the cost of production. Additionally, the government has been investing in the healthcare sector to improve the quality of healthcare services and increase access to healthcare products.
Underlying macroeconomic factors: The growth of the Other Pharmaceuticals market in Nigeria can be attributed to the favorable macroeconomic environment in the country. Nigeria has been experiencing steady economic growth, which has resulted in an increase in disposable income and an expanding middle class. Additionally, the government has been implementing policies to attract foreign investment, which has resulted in an increase in foreign direct investment in the country. The increase in foreign investment has led to the transfer of technology and the development of local manufacturing capabilities.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
